Last reviewed · How we verify
Risperidone tablets
Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.
Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar disorder (acute mania and maintenance), Irritability associated with autism spectrum disorder.
At a glance
| Generic name | Risperidone tablets |
|---|---|
| Also known as | Risperdal |
| Sponsor | Sumitomo Pharma (Suzhou) Co., Ltd. |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor; Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | FDA-approved |
Mechanism of action
Risperidone is an atypical antipsychotic that antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis such as hallucinations and delusions. It also blocks serotonin 5-HT2A receptors, which contributes to its efficacy in treating negative symptoms and mood disturbances. This dual antagonism distinguishes it from typical antipsychotics and is associated with a lower risk of extrapyramidal side effects.
Approved indications
- Schizophrenia
- Bipolar disorder (acute mania and maintenance)
- Irritability associated with autism spectrum disorder
- Behavioral disturbances in dementia
Common side effects
- Weight gain
- Sedation
- Extrapyramidal symptoms (tremor, rigidity, akathisia)
- Prolactin elevation (galactorrhea, amenorrhea)
- Orthostatic hypotension
- Metabolic syndrome
- Akathisia
Key clinical trials
- Supportive Psychotherapy as Adjunct to Risperidone for Cognitive Function and Inflammation in Schizophrenia (PHASE2)
- Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008) (PHASE2)
- Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use (PHASE2)
- A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment (PHASE3)
- "Extended" (Alternate Day) Antipsychotic Dosing (PHASE4)
- A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (PHASE3)
- A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities (PHASE4)
- A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Risperidone tablets CI brief — competitive landscape report
- Risperidone tablets updates RSS · CI watch RSS
- Sumitomo Pharma (Suzhou) Co., Ltd. portfolio CI